Dabigatran in patients with nonvalvular atrial fibrillation

Journal of the American College of Cardiology

Volumn 58, Issue 5, 2011, Pages 551-

  Gage, Lawrence ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DABIGATRAN; WARFARIN;

BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; UNITED STATES;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 79960586319     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.04.016     Document Type: Letter

References (3)

1. L.S. Wann, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 57 2011 1330 1337
2. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
3. Center for Drug Evaluation and Research, Application number 22-512, Summary Review, Deputy Office Director Decisional Memo, October 19, 2010: page 15 http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022512Orig1s000SumR. pdf Accessed March 28, 2011